Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: Type 508 Accommodation and the title of the report in the subject line of e-mail.

Notice to Readers: Recall of LCx® Neisseria gonorrhoeae Assay and Implications for Laboratory Testing for N. gonorrhoeae and Chlamydia trachomatis

On July 18, 2002, Abbott Laboratories (Abbott Park, IL) initiated a voluntary recall of its LCx® Neisseria gonorrhoeae Assay (List Numbers 8A48-81 and 8A48-82) because, during routine quality assurance testing, several reagent lots failed to meet the analytical sensitivity described in the product insert. The cause of the failure is under investigation by the company. Abbott Laboratories has sent a letter to its customers informing them of this recall and the specific reagent lot numbers not meeting the analytical sensitivity.

The possibility of false-negative results for specimens tested with affected lots has prompted the following actions:

  1. 1. As recommended by Abbott Laboratories, laboratories should discontinue use of and discard any remaining LCx® N. gonorrhoeae assay reagents.
  2. 2. Laboratories that have tested specimens using the affected lots should notify their consumers (e.g., health care agencies and clinicians) about the increased risk for a false-negative result on such specimens. Notifications should be documented as required by the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
  3. 3. For patients whose specimens were tested with the affected lots, clinicians should offer retesting to patients whose test results were negative and who were not presumptively treated.

Separate LCx® assays for the detection of Chlamydia trachomatis and N. gonorrhoeae have been cleared by the Food and Drug Administration (FDA). Although the LCx® C. trachomatis Assay has not been recalled, public health departments have reported delays in obtaining both assays.

For laboratories unable to test specimens for C. trachomatis and N. gonorrhoeae because of the unavailability of LCx® assay reagents, several testing options are available:

  1. 1. Testing with the LCx® assays can be delayed. Urine specimens or endocervical or urethral swab specimens collected for LCx® testing can be stored at -4o F (-20o C) for up to 60 days before testing with the assay.
  2. 2. For more timely patient management, the use of other FDA-cleared tests should be considered. Urine specimens that have not been processed for LCx® testing can be tested by using another FDA-cleared nucleic acid amplification test. Only nucleic acid amplification tests are recommended for the direct detection of C. trachomatis or N. gonorrhoeae in urine. Swab specimens collected from patients and placed in LCx® transport medium cannot be tested by using another FDA-cleared test. Health-care providers should consider recalling such patients to collect a new specimen for testing with another FDA-cleared test. If this is done, the laboratory should be consulted about procedures for proper swab collection. Laboratories also could consider culture as an option to test for N. gonorrhoeae.
  3. 3. In addition, laboratories may consider redirecting their consumers to other laboratories that can provide such screening services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Page converted: 8/15/2002


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services

This page last reviewed 8/15/2002